Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Zyversa Therapeutics Inc ZVSA

Healthcare Biotechnology
ZyVersa Therapeutics, Inc. is a clinical-stage specialty biopharmaceutical company. The Company is focused on leveraging advanced technologies to develop drugs for patients with chronic renal or inflammatory diseases. Its lead renal drug candidate Cholesterol Efflux Mediator VAR 200 (2-hydroxypropyl-beta-cyclodextrin or 2HBCD) is in development to treat multiple renal indications. Its lead anti-inflammatory drug candidate, Inflammasome ASC Inhibitor IC 100, is a humanized monoclonal antibody in development to treat multiple inflammatory diseases. Its renal pipeline is initially focused on rare, chronic glomerular diseases. Its lead indication for VAR 200 is focal segmental glomerulosclerosis (FSGS). VAR 200’s active ingredient, 2HBCD, is comprised of seven sugar molecules bound together in a 3-D ring with a hydrophobic core and hydrophilic exterior. VAR 200 mediates cholesterol efflux both passively and actively by interacting with hydrophilic components of the glomerular membrane.


NDAQ:ZVSA - Post by User

Zyversa Therapeutics Inc > ZVSA.....I'd say we get some "sideways action" for a awhile
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(72)
•••
Post by Iseneschalon Nov 05, 2024 10:24am
19 Views
Post# 36296961

ZVSA.....I'd say we get some "sideways action" for a awhile

ZVSA.....I'd say we get some "sideways action" for a awhile possible bounce and vol spike

If ur in ....use it to sell...currently at $2.60


JMHO
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities